%0 Journal Article %A Eghbali, Aziz %A Fadayi, Fatemeh %A Ghandi, Yazdan %A Falahati, Vahid %A Bagheri, Bahador %T Efficacy of High Dose Vitamin D on Pulmonary Artery Pressure in Thalassemia Patients Undergoing Blood Transfusion: A Randomized Trial %J Iranian journal of Pediatric Hematology and Oncology %V 12 %N 4 %U http://ijpho.ssu.ac.ir/article-1-703-en.html %R 10.18502/ijpho.v12i4.10912 %D 2022 %K Ejection fraction, Pulmonary arterial hypertension, Thalassemia, Vitamin D, %X Background: Pulmonary arterial hypertension (PAH) may result in cardiomyopathy which is a major cause of death in thalassemia patients. Vitamin D is associated with benefits in cardiovascular disorders. Our purpose was to study effects of vitamin D on pulmonary artery pressure in thalassemia major and intermedia patients. Materials and Methods: This randomized trial was performed on 26 patients with thalassemia major (TM) and intermedia (TI) in Amir-Kabir Hospital, Arak, Iran in 2019-2020. Patients were randomized 1:1 to intervention group (vitamin D 50,000 IU/week) and control group (received no supplement) for 20 weeks. Echocardiography was used to measure pulmonary artery pressure and assess cardiovascular function. The levels of 1,25-dihydroxyvitamin D3, ferritin, and cardiac iron content were measured in study groups. Results: After 20 weeks, pulmonary arterial pressure (PAP), tricuspid regurgitant velocity (TRV), and pulmonary regurgitant velocity (PRV) significantly improved in the intervention group compared to the control group (P= 0.010, P= 0.003, and P= 0.001, respectively). Moreover, ejection fraction (EF) had significant increase in the intervention group compared to the control group (P= 0.008), although vitamin D supplementation had no significant impact on cardiac T2* values (P= 0.827), systolic and diastolic blood pressure (P= 0.388 and P= 0.509, respectively) and serum hemoglobin and ferritin levels (P= 0.557 and P= 0.620) as compared to the control group. However, the levels of 25-OHD3 significantly increased in the intervention group compared to the control group (P= 0.036). Conclusion: This study showed that vitamin D 50000 IU/week can improve PAP in patients with thalassemia. Sufficient intake of vitamin D may prevent cardiomyopathies related to PAH. %> http://ijpho.ssu.ac.ir/article-1-703-en.pdf %P 220-228 %& 220 %! %9 Research %L A-10-534-3 %+ Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland %G eng %@ 2008-8892 %[ 2022